Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients.
Adolescent
Adult
Aged
Aged, 80 and over
Arginase
/ blood
B7-H1 Antigen
/ blood
Biomarkers, Tumor
/ blood
Female
Glioma
/ blood
Humans
Immunocompromised Host
Immunophenotyping
Leukocytes, Mononuclear
/ immunology
Liquid Biopsy
Male
Middle Aged
Myeloid Cells
/ immunology
Myeloid-Derived Suppressor Cells
/ immunology
Neoplasm Grading
Neoplasm Staging
Prognosis
STAT3 Transcription Factor
/ blood
Young Adult
STAT3
arginase 1 (ARG1)
biomarkers
glioma
myeloid-derived suppressor cell
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
11
2021
accepted:
13
12
2021
entrez:
24
1
2022
pubmed:
25
1
2022
medline:
8
3
2022
Statut:
epublish
Résumé
Although gliomas are confined to the central nervous system, their negative influence over the immune system extends to peripheral circulation. The immune suppression exerted by myeloid cells can affect both response to therapy and disease outcome. We analyzed the expansion of several myeloid parameters in the blood of low- and high-grade gliomas and assessed their relevance as biomarkers of disease and clinical outcome. Peripheral blood was obtained from 134 low- and high-grade glioma patients. CD14 Changes in myeloid parameters associated with immune suppression allowed to define a diagnostic score calculating the risk of being a glioma patient. The same parameters, together with age, permit to calculate the risk score in differentiating each glioma grade. A prognostic model for glioblastoma patients stemmed out from a Cox multiple analysis, highlighting the role of MDSC, p-STAT3, and ARG1 activity together with clinical parameters in predicting patient's outcome. This work emphasizes the role of systemic immune suppression carried out by myeloid cells in gliomas. The identification of biomarkers associated with immune landscape, diagnosis, and outcome of glioblastoma patients lays the ground for their clinical use.
Sections du résumé
Background
Although gliomas are confined to the central nervous system, their negative influence over the immune system extends to peripheral circulation. The immune suppression exerted by myeloid cells can affect both response to therapy and disease outcome. We analyzed the expansion of several myeloid parameters in the blood of low- and high-grade gliomas and assessed their relevance as biomarkers of disease and clinical outcome.
Methods
Peripheral blood was obtained from 134 low- and high-grade glioma patients. CD14
Results
Changes in myeloid parameters associated with immune suppression allowed to define a diagnostic score calculating the risk of being a glioma patient. The same parameters, together with age, permit to calculate the risk score in differentiating each glioma grade. A prognostic model for glioblastoma patients stemmed out from a Cox multiple analysis, highlighting the role of MDSC, p-STAT3, and ARG1 activity together with clinical parameters in predicting patient's outcome.
Conclusions
This work emphasizes the role of systemic immune suppression carried out by myeloid cells in gliomas. The identification of biomarkers associated with immune landscape, diagnosis, and outcome of glioblastoma patients lays the ground for their clinical use.
Identifiants
pubmed: 35069595
doi: 10.3389/fimmu.2021.809826
pmc: PMC8777055
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
ARG1 protein, human
EC 3.5.3.1
Arginase
EC 3.5.3.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
809826Informations de copyright
Copyright © 2022 Del Bianco, Pinton, Magri, Canè, Masetto, Basso, Padovan, Volpin, d’Avella, Lombardi, Zagonel, Bronte, Della Puppa and Mandruzzato.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncoimmunology. 2016 Nov 1;5(12):e1249559
pubmed: 28123888
Front Immunol. 2018 Sep 27;9:2129
pubmed: 30356906
Nat Rev Immunol. 2021 Aug;21(8):485-498
pubmed: 33526920
J Neurooncol. 2021 Jan;151(1):3-12
pubmed: 32542437
J Immunother Cancer. 2019 Feb 27;7(1):58
pubmed: 30813960
Nat Rev Neurol. 2015 Oct;11(10):556-66
pubmed: 26369507
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385717
Immunity. 2016 Feb 16;44(2):303-15
pubmed: 26885857
J Leukoc Biol. 2011 May;89(5):721-7
pubmed: 21330347
Nat Rev Cancer. 2019 Mar;19(3):162-175
pubmed: 30696923
Nat Med. 2012 Aug;18(8):1254-61
pubmed: 22842478
J Clin Invest. 2015 Sep;125(9):3365-76
pubmed: 26325033
Drug Discov Today. 2018 Apr;23(4):871-878
pubmed: 29391126
J Neurooncol. 2018 May;137(3):503-510
pubmed: 29349612
Cancers (Basel). 2020 Aug 14;12(8):
pubmed: 32823925
JAMA Oncol. 2020 Jul 1;6(7):1003-1010
pubmed: 32437507
Cancer Immunol Immunother. 2016 Feb;65(2):161-9
pubmed: 26728481
Oncoimmunology. 2018 Aug 27;7(11):e1507668
pubmed: 30377570
J Neuropathol Exp Neurol. 2015 May;74(5):390-400
pubmed: 25853692
J Neurooncol. 2017 Aug;134(1):189-196
pubmed: 28551851
J Immunol. 2009 May 15;182(10):6562-8
pubmed: 19414811
Neuro Oncol. 2016 Sep;18(9):1253-64
pubmed: 27006175
J Immunother Cancer. 2019 Sep 18;7(1):255
pubmed: 31533831
J Clin Invest. 2013 Apr;123(4):1580-9
pubmed: 23454751
Blood. 2011 Aug 25;118(8):2254-65
pubmed: 21734236
Oncoimmunology. 2018 Jul 30;7(10):e1494113
pubmed: 30288362
Neuro Oncol. 2011 Jun;13(6):591-9
pubmed: 21636707
Cancer Immunol Immunother. 2009 Jan;58(1):49-59
pubmed: 18446337
Nat Protoc. 2006;1(3):1522-30
pubmed: 17406444
JCI Insight. 2019 Nov 14;4(22):
pubmed: 31600167
Stem Cells. 2016 Aug;34(8):2026-39
pubmed: 27145382
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Front Immunol. 2020 Jul 24;11:1590
pubmed: 32793228
Ann N Y Acad Sci. 2014 Jun;1319:47-65
pubmed: 24965257
Clin Cancer Res. 2019 Jun 15;25(12):3643-3657
pubmed: 30824583
Clin Cancer Res. 2011 Nov 15;17(22):6992-7002
pubmed: 21948231
Cytometry B Clin Cytom. 2015 Mar;88(2):77-91
pubmed: 25504825
JCI Insight. 2016;1(2):
pubmed: 26973881
Am Fam Physician. 2000 Nov 1;62(9):2053-60
pubmed: 11087187
Cancer Discov. 2020 Aug;10(8):1210-1225
pubmed: 32300059
Cell Rep. 2020 Dec 29;33(13):108571
pubmed: 33378668
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Neuro Oncol. 2016 Feb;18(2):206-15
pubmed: 26180083